Galidesivir

• Description:

  Galidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM[1][2][3].

• Product Name Alternative:

  BCX4430; Immucillin-A

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  DNA/RNA Synthesis; Filovirus; SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/BCX4430-freebase.html

• Purity:

  99.29

• Solubility:

  H2O : 100 mg/mL (ultrasonic)

• Smiles:

  O[C@H]1[C@H](C2=CNC3=C2N=CN=C3N)N[C@H](CO)[C@H]1O

• Molecular Formula:

  C11H15N5O3

• Molecular Weight:

  265.27

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]Elfiky AA, et al. ICN-1229, Remdesivir, PSI-7977, Galidesivir, and GS 1278 against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) : A molecular docking study. Life Sci. 2020 Mar 25:117592.|[2]Taylor R, et al. BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health. 2016;9 (3) :220-226.|[3]Warren TK, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508 (7496) :402-405.|[4]Julander JG, et al. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. Antimicrob Agents Chemother. 2014;58 (11) :6607-6614.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Citation 01:

  Antiviral Res. 2017 Jun:142:63-67.|Biomed Pharmacother. 2025 Apr 28:187:118104.|bioRxiv. 2025 January 29.|bioRxiv. 2025 Sep 22.|Exp Ther Med. 2016 Sep;12 (3) :1812-1816. |Microorganisms. 2021 Mar 31;9 (4) :734.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Virology. 2023 Aug:585:21-31.|Viruses. 2020 Jun 10;12 (6) :628.|Antimicrob Agents Chemother. 2019 Feb 26;63 (3) :e02093-18.|Antiviral Res. 2017 Jun:142:63-67.|bioRxiv. 2025 April 22.|J AOAC Int. 2024 Jun 13:qsae047.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.

• CAS Number:

  [249503-25-1]